Zeitschrift fur Gastroenterologie最新文献_第8页

Recurrent Non-islet Cell Tumor Hypoglycemia Secondary to Hepatocellular Carcinoma: Case Report and Literature Review. 肝细胞癌继发的复发性非胰岛细胞肿瘤低血糖症：病例报告和文献复习。

IF 1.4 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2024-05-01 Epub Date: 2023-10-05 DOI: 10.1055/a-2170-1691

Dan He, Hongpeng Gong, Jie Pan, Fangchao Zhu, Xiaofen Jiang, Huang Su

{"title":"Recurrent Non-islet Cell Tumor Hypoglycemia Secondary to Hepatocellular Carcinoma: Case Report and Literature Review.","authors":"Dan He, Hongpeng Gong, Jie Pan, Fangchao Zhu, Xiaofen Jiang, Huang Su","doi":"10.1055/a-2170-1691","DOIUrl":"10.1055/a-2170-1691","url":null,"abstract":"Rationale: Non-islet cell tumor hypoglycemia (NICTH) is a paraneoplastic syndrome caused by tumors other than insulinoma that is primarily due to excessive production of insulin-like growth factor-II (IGF-II). The prevalence of NICTH is likely underestimated because of a lack of clinical recognition.Patient concerns: A 41-year-old male with massive malignant liver tumors presented with recurrent severe hypoglycemia, weight loss, and liver cirrhosis.Diagnosis: NICTH related to IGF-II produced by hepatocellular carcinoma was diagnosed based on clinical symptoms, biochemical tests, and elevated IGF-II/IGF-I ratio.Intervention: Initial treatment with intravenous glucose and parenteral nutrition showed limited efficacy. Glucocorticoids and recombinant human growth hormone led to progressive improvement in blood glucose levels.Outcome: Due to extensive tumor burden and liver failure, surgical resection was not feasible, and the patient ultimately succumbed to refractory hypoglycemia and passed away in two weeks.Lessons: Early recognition and diagnosis of NICTH are crucial in patients with recurrent hypoglycemia and large tumors. Surgical resection is the preferred treatment option, but supportive care and pharmacological interventions, such as glucocorticoids and growth hormone, can help manage refractory hypoglycemia. Further research is needed to explore novel treatment options, including anti-IGF-I and -IGF-II neutralizing antibodies.","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":" ","pages":"752-758"},"PeriodicalIF":1.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41156851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2). 溃疡性结肠炎 S3 指南更新版（6.2 版）。

IF 1.4 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2024-05-01 Epub Date: 2024-05-08 DOI: 10.1055/a-2271-0994

T Kucharzik, A Dignass, R Atreya, B Bokemeyer, P Esters, K Herrlinger, K Kannengiesser, P Kienle, J Langhorst, A Lügering, S Schreiber, A Stallmach, J Stein, A Sturm, N Teich, B Siegmund

引用次数: 0

Leitlinienreport der aktualisierten S3-Leitlinie Colitis ulcerosa der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). 德国胃肠病、消化和代谢疾病学会（DGVS）溃疡性结肠炎 S3 更新指南报告。

IF 1.4 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2024-05-01 Epub Date: 2024-05-08 DOI: 10.1055/a-2271-1065

Pia Lorenz, Axel Dignass, Torsten Kucharzik, Petra Lynen Jansen

引用次数: 0

[Quality of life of ostomates in Germany]. [德国造口术患者的生活质量]。

IF 1.3 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2024-04-01 Epub Date: 2023-09-26 DOI: 10.1055/a-2163-5299

Peter C Ambe, Jessica Breuing, Erich Grohnmann, Nicole Engel, Dawid Pieper, Hubert Zirngibl, Charlotte Kugler

{"title":"[Quality of life of ostomates in Germany].","authors":"Peter C Ambe, Jessica Breuing, Erich Grohnmann, Nicole Engel, Dawid Pieper, Hubert Zirngibl, Charlotte Kugler","doi":"10.1055/a-2163-5299","DOIUrl":"10.1055/a-2163-5299","url":null,"abstract":"Background: The presence of an ostomy may have a serious impact on the quality of life (QoL). The aim of this study was to evaluate the QoL of ostomates in Germany.Method: An online survey was performed using the validated Gastrointestinal Quality of Life Index (GIQLI) by Eypasch et al. Ostomates ≥ 18 yrs. with an ostomy duration ≥ 3 months were eligible to participate.Results: Completed questionnaires from 519 participants (79.3 % female) with a median age of 50 yrs. (range 19-83 yrs.) and a median ostomy duration of 3 yrs. (range 3 months-58 yrs.) were analyzed. The most common indications for an ostomy were Crohn's disease (36.5 %), colorectal cancer (19.8 %) and ulcerative colitis (18.2 %). The mean GIQLI-Score in the study population was 94.8 ± 24.6, with higher scores corresponding with better QoL and healthy individuals reach 125.8. Limitations were recorded with regard to sleep, tiredness, energy level, endurance, fitness and sexuality. Individuals with a stoma due to Colitis (103,0 ± 24,5), colorectal cancer (99,2 ± 21,7) and Crohn's (95,0 ± 22,8) had the highest mean GIQLI-scores amongst all ostomates.Discussion: The findings of this study confirm that ostomates have a reduced QoL compared to the healthy population. Amongst all ostomates, those with colitis, colorectal cancer and Crohn's have a better QoL compared to ostomy carriers with other diagnoses.","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":" ","pages":"473-478"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41177165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[1983-2023 - Four decades Helicobacter pylori - what's next?] [1983-2023--幽门螺旋杆菌四十年--下一步是什么？］

IF 1.3 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2024-04-01 Epub Date: 2024-01-18 DOI: 10.1055/a-2207-7185

Christian Schulz, Kerstin Schütte, Alexander Link, Peter Malfertheiner

引用次数: 0

Percutaneous drainage and combined praziquantel-albendazole therapy: a novel approach for the treatment of simple echinococcal liver cysts. 经皮引流和吡喹酮-阿苯达唑联合治疗：一种治疗单纯性棘球蚴肝囊肿的新方法。

IF 1.3 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2024-04-01 Epub Date: 2023-09-20 DOI: 10.1055/a-2084-3735

Joachim Richter, Andreas K Lindner, Dominik Geisel, Florian Nima Fleckenstein, Giovanni Federico Torsello, Belén Millet Pascual-Leone, Olga Ivanov, Caroline Zöllner, Anne-Christine Beatrix Wilde, Gabriela Equihua Martinez

{"title":"Percutaneous drainage and combined praziquantel-albendazole therapy: a novel approach for the treatment of simple echinococcal liver cysts.","authors":"Joachim Richter, Andreas K Lindner, Dominik Geisel, Florian Nima Fleckenstein, Giovanni Federico Torsello, Belén Millet Pascual-Leone, Olga Ivanov, Caroline Zöllner, Anne-Christine Beatrix Wilde, Gabriela Equihua Martinez","doi":"10.1055/a-2084-3735","DOIUrl":"10.1055/a-2084-3735","url":null,"abstract":"Cystic echinococcosis (CE) is a worldwide helminthic zoonosis causing serious disease in humans. The WHO Informal Working Group on Echinococcosis recommends a stage-specific treatment approach of hepatic CE that facilitates the decision on what therapy option is most appropriate. Percutaneous aspiration, instillation of a scolicide, e.g., ethanol or hypertonic saline, and subsequent re-aspiration (PAIR) have been advocated for treating medium-size unilocular WHO-stage CE1 cysts. PAIR can pose a risk of toxic cholangitis because of spillage of ethanol in the case of a cysto-biliary fistula or of life-threatening hypernatriaemia when hypertonic saline is used. The purpose of our study is to develop an alternative, safe, minimally invasive method to treat CE1 cysts, avoiding the use of toxic topic scolicides.We opt for percutaneous drainage (PD) in four patients: the intrahepatic drainage catheter is placed under CT-fluoroscopy, intracystic fluid is aspirated, and the viability of intracystic echinococcal protoscolices is assessed microscopically. Oral praziquantel (PZQ) is added to albendazole (ABZ) instead of using topical scolicidals.Protoscolices degenerate within 5 to 10 days after PZQ co-medication at a cumulative dosage of 250 to 335 mg/kg, and the cysts collapse. The cysts degenerate, and no sign of spillage nor relapse is observed in the follow-up time of up to 24 months post-intervention.In conclusion, PD combined with oral PZQ under ABZ coverage is preferable to PAIR in patients with unilocular echinococcal cysts.","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":" ","pages":"500-507"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41164268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus. 食道鳞状细胞癌和腺癌的诊断和治疗 S3 指南。

IF 1.3 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2024-04-01 Epub Date: 2024-04-10 DOI: 10.1055/a-2239-9802

Matthias P Ebert, Wolfgang Fischbach, Stephan Hollerbach, Jens Höppner, Dietmar Lorenz, Michael Stahl, Martin Stuschke, Oliver Pech, Udo Vanhoefer, Rainer Porschen

引用次数: 0

[A critical DRG-evaluation of cases with inflammatory bowel disease]. [炎症性肠病病例的关键DRG评估]。

IF 1.3 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2024-04-01 Epub Date: 2023-10-12 DOI: 10.1055/a-2075-2533

Maria Moll-von der Wettern, Wolfgang Heinlein, Markus Rathmayer, Lisa Koller, Jörg G Albert, Britta Siegmund

{"title":"[A critical DRG-evaluation of cases with inflammatory bowel disease].","authors":"Maria Moll-von der Wettern, Wolfgang Heinlein, Markus Rathmayer, Lisa Koller, Jörg G Albert, Britta Siegmund","doi":"10.1055/a-2075-2533","DOIUrl":"10.1055/a-2075-2533","url":null,"abstract":"Introduction: Whether inpatients with inflammatory bowel disease (IBD) are reimbursed in a cost-covering manner in German hospitals has not yet been investigated. In this context, the present study analyses the reimbursement situation (cost-revenue comparison) of IBD in German hospitals with regard to the complexity of the disease and the type of care.Methods: For this retrospective study, anonymized case data, including cost data from the InEK calculation (§ 21-4 KHEntgG) of the DRG project of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS) from 2019, were available. 3385 cases with IBD the as main diagnosis from 49 hospitals were analyzed. To investigate the impact of disease complexity on reimbursement, different variables were analyzed, including gastroenterological complications, infections, the reason for admission, and additional charges. To investigate possible center effects, hospitals were grouped by type of care, mostly defined by the number of beds.Results: The present study shows that all types of care can be classified as not cost-covering on average. The under-recovery is, on average, 10% (296 € absolute under-recovery) and varies between the types of care. Cases with higher complexity show a higher cost under-recovery than cases with lower complexity. At the DRG level, the analyzed costs of the three most common IBD DRGs for inlier patients are higher than the InEK costs; however, the difference is not significant. Nonetheless, cases with the admission reason transfer of specific DRGs bear significantly higher costs.Discussion: Our results show that CED is not reimbursed in a cost-covering manner. This is due to inadequate reimbursement for gastroenterological complications, infections, specific procedures, and emergency and transfer cases. Transfer cases bear significantly higher costs.","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":" ","pages":"479-489"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41214436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Fecal Microbiota Transfer (FMT) in Germany - Status and Perspective]. [德国的粪便微生物群转移（FMT）--现状与展望]。

IF 1.3 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2024-04-01 Epub Date: 2023-05-15 DOI: 10.1055/a-2075-2725

Andreas Stallmach, Lutz von Müller, Martin Storr, Alexander Link, Peter C Konturek, Philipp Christoph Solbach, Karl Heinz Weiss, Steffen Wahler, Maria J G T Vehreschild

{"title":"[Fecal Microbiota Transfer (FMT) in Germany - Status and Perspective].","authors":"Andreas Stallmach, Lutz von Müller, Martin Storr, Alexander Link, Peter C Konturek, Philipp Christoph Solbach, Karl Heinz Weiss, Steffen Wahler, Maria J G T Vehreschild","doi":"10.1055/a-2075-2725","DOIUrl":"10.1055/a-2075-2725","url":null,"abstract":"Introduction: Fecal microbiota transfer (FMT) is a treatment to modulate the gastrointestinal microbiota. Its use in recurrent Clostridioides difficile infection (rCDI) is established throughout Europe and recommended in national and international guidelines. In Germany, the FMT is codeable in the hospital reimbursement system. A comprehensive survey on the frequency of use based on this coding is missing so far.Material and methodology: Reports of the Institute for Hospital Remuneration (InEK), the Federal Statistical Office (DESTATIS), and hospital quality reports 2015-2021 were examined for FMT coding and evaluated in a structured expert consultation.Results: Between 2015 and 2021, 1,645 FMT procedures were coded by 175 hospitals. From 2016 to 2018, this was a median of 293 (274-313) FMT annually, followed by a steady decline in subsequent years to 119 FMT in 2021. Patients with FMT were 57.7% female, median age 74 years, and FMT was applied colonoscopically in 72.2%. CDI was the primary diagnosis in 86.8% of cases, followed by ulcerative colitis in 7.6%.Discussion: In Germany, FMT is used less frequently than in the European comparison. One application hurdle is the regulatory classification of FMT as a non-approved drug, which leads to significantly higher costs in manufacturing and administration and makes reimbursement difficult. The European Commission recently proposed a regulation to classify FMT as a transplant. This could prospectively change the regulatory situation of FMT in Germany and thus contribute to a nationwide offer of a therapeutic procedure recommended in guidelines.","PeriodicalId":23853,"journal":{"name":"Zeitschrift fur Gastroenterologie","volume":" ","pages":"490-499"},"PeriodicalIF":1.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Moderately severe acute pancreatitis after snake bite: a case report from Southern China. 中国南方一例蛇咬伤后中重度急性胰腺炎病例报告。

IF 1.3 4区医学

Zeitschrift fur Gastroenterologie Pub Date : 2024-04-01 Epub Date: 2023-09-20 DOI: 10.1055/a-2150-2291

Ronglai Cao, Jinli He, Zhengping Yu, Youxiang Chen, Liang Zhu

引用次数: 0